2021 Essex County Council election

Lunit Highlights the Effectiveness of AI in Predicting Cancer Treatment Outcomes - Findings to be Presented at ASCO GI 2023

Retrieved on: 
Wednesday, January 18, 2023

As a leading provider of state-of-the-art cancer diagnostic technology, Lunit has focused on developing novel AI biomarkers for application in immunotherapy.

Key Points: 
  • As a leading provider of state-of-the-art cancer diagnostic technology, Lunit has focused on developing novel AI biomarkers for application in immunotherapy.
  • This year, Lunit's presentations at ASCO GI 2023 will highlight the effectiveness of Lunit SCOPE IO as a biomarker to predict liver and colon cancer treatment outcomes.
  • Lunit SCOPE IO assesses a patient's cancer tissue slide image by analyzing the distribution of tumor-infiltrating lymphocytes (TILs)—one of the representative immunocytes that fight cancer cells.
  • One of the studies to be presented investigates the correlation between AI-powered immune phenotype and real-world outcomes in liver cancer.

Caris Life Sciences to Showcase Extensive Research with Leading Cancer Centers at ASCO Gastrointestinal Cancers Symposium 2023 Reflecting Its Commitment to Improving Outcomes for Patients

Retrieved on: 
Tuesday, January 17, 2023

IRVING, Texas, Jan. 17, 2023 /PRNewswire/ -- Caris Life Sciences®(Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, today announced that the company and partners within the Caris Precision Oncology Alliance™ (POA) will collectively present 18 studies across more than six tumor types at the 2023 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, January 19-21, 2023 in San Francisco (Tabletop #70).

Key Points: 
  • "The findings represent important observations in a variety of tumors, including rare tumors and new tumor sub-types, which could lead to novel therapeutic approaches and improved outcomes for patients."
  • (Poster Number: L4)
    Survival of patients with colorectal cancer (CRC) with low expression of homologous recombination proficient (HRP) genes.
  • (Poster Number: M7)
    Poster and abstract summaries highlighting this research will be available onsite at Caris' Tabletop #70.
  • The Caris Precision Oncology Alliance includes 75 cancer centers and academic institutions in the United States and beyond.

FLOW-3D World Users Conference 2023 to take place in Strasbourg, France

Retrieved on: 
Tuesday, January 17, 2023

SANTA FE, N.M., Jan. 17, 2023 /PRNewswire-PRWeb/ -- Co-hosted by XC Engineering, the official distributor of FLOW-3D products in Italy and France, this year's conference features application-specific tracks, advanced training sessions, in-depth technical presentations by FLOW-3D users, and the latest product developments presented by Flow Science's senior technical staff.

Key Points: 
  • Flow Science, Inc. will hold the FLOW-3D World Users Conference 2023 on June 5-7, 2023 at the Sofitel Strasbourg Grande Ile in Strasbourg, France.
  • "This year's world users conference promises to be one of our largest events ever.
  • Every year, the world users conference provides a great opportunity to exchange ideas and take the simulation component of our attendees to the next level.
  • Advanced training sessions for FLOW-3D's family of products will be offered as part of the conference.

RenovoRx Announces Initial Results in Pharmacokinetic (PK) Substudy: Data on RenovoGem™ Supports Potential for RenovoTAMP® Therapy Platform to Increase Local Gemcitabine (Chemotherapy) Delivery and Decrease Side Effects of Pancreatic Cancer Treatment

Retrieved on: 
Wednesday, January 18, 2023

The TIGeR-PaC clinical trial is evaluating intra-arterial (IA) administration of gemcitabine (chemotherapy) using the proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP) platform for targeted treatment of Locally Advanced Pancreatic Cancer (LAPC).

Key Points: 
  • The TIGeR-PaC clinical trial is evaluating intra-arterial (IA) administration of gemcitabine (chemotherapy) using the proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP) platform for targeted treatment of Locally Advanced Pancreatic Cancer (LAPC).
  • The substudy concludes that RenovoTAMP may increase local gemcitabine concentration, which may be beneficial in decreasing gemcitabine-related systemic side effects.
  • “Targeted local delivery of standard dose gemcitabine via the RenovoTAMP therapy platform may be associated with significantly less systemic drug exposure.
  • The poster presentations for the four RenovoRx abstracts to be presented at the ASCO GI Symposium will be available on RenovoRx’s website once available: https://renovorx.com/for-clinicians/ .

Guardant Health to showcase new data at ASCO GI 2023 demonstrating utility of its blood tests for patients with gastrointestinal cancers

Retrieved on: 
Tuesday, January 17, 2023

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that new data from its portfolio of blood tests will be presented at the ASCO 2023 Gastrointestinal Cancers Symposium, January 19-21 in San Francisco.

Key Points: 
  • Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that new data from its portfolio of blood tests will be presented at the ASCO 2023 Gastrointestinal Cancers Symposium, January 19-21 in San Francisco.
  • The 10 poster presentations highlight the use of the Guardant360® and Guardant RevealTM blood tests and the GuardantINFORMTM real-world evidence dataset to identify critical biomarkers and acquired co-mutations, track associated treatment patterns and clinical outcomes, and predict disease recurrence from minimal residual disease (MRD) detection.
  • “We look forward to sharing new data at the ASCO GI Symposium demonstrating the utility of our blood tests and real-world data to increase the understanding of potential biomarker targets for therapy, as well as predictive markers for treatment resistance and disease recurrence in patients with gastrointestinal cancers,” said Helmy Eltoukhy, Guardant Health co-CEO.
  • “The presentations will show how data from circulating tumor DNA tests provide critical insights that can contribute to the development of more effective therapies and better-informed patient care.”
    FGFR2-amplified gastroesophageal adenocarcinoma is a distinct genomic class: Lessons learned from a liquid biopsy platform (abstract 429)
    The full abstracts are available on the official ASCO 2023 GI Cancers Symposium website.

Jasper Therapeutics Announces New Positive Briquilimab Data to be Presented at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR

Retrieved on: 
Friday, January 13, 2023

REDWOOD CITY, Calif., Jan. 13, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper” or the “Company”), a biotechnology company developing novel antibody therapies addressing chronic diseases such as urticaria, lower-risk myelodysplastic syndromes (MDS) and stem cell transplant conditioning agents targeting c-Kit, today announced that new positive data for briquilimab (formerly known as JSP191), will be presented at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, taking place on February 15-19, 2023 in Orlando, Florida.

Key Points: 
  • Based on its mechanism of action, briquilimab is known to potently synergize with radiation, amplifying its stem cell depleting effects without increasing off-target toxicity.
  • The first abstract demonstrates that briquilimab was safe, well-tolerated, and achieved durable remissions in 8 of 12 of the first treated AML patients.
  • During the first 100 days post-procedure there were a total of 7 hospitalizations in the 12 patients, with an overall mean stay of 4 days.
  • These results demonstrate the feasibility and potential significant cost savings of outpatient briquilimab plus Flu/TBI conditioning followed by outpatient donor cell transplant in older patients with AML or MDS.

Unicycive Announces Acceptance of Four Abstracts for Presentation at the World Congress of Nephrology 2023

Retrieved on: 
Thursday, January 5, 2023

LOS ALTOS, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that four abstracts have been accepted for presentation at the upcoming International Society of Nephrology’s World Congress of Nephrology 2023 meeting taking place in Bangkok, Thailand from March 30 – April 2, 2023.

Key Points: 
  • LOS ALTOS, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that four abstracts have been accepted for presentation at the upcoming International Society of Nephrology’s World Congress of Nephrology 2023 meeting taking place in Bangkok, Thailand from March 30 – April 2, 2023.
  • “With our recently announced successful bioequivalence study of Renazorb compared to Fosrenol®, we are looking forward to filing a New Drug Application with the U.S. Food and Drug Administration in mid-2023.
  • These data provide further evidence of the benefits of Renazorb as a powerful phosphate binder and highlight its enhanced product profile, which is expected to improve medication compliance and, thereby, improve outcomes and quality-of-life for patients.”
    “The exposure of these favorable data before an audience of international nephrologists should further expand awareness of the advantages of Renazorb to treat hyperphosphatemia and should bolster our positioning in any potential partnership or licensing discussions,” added Dr. Gupta.
  • Fosrenol is a registered trademark of Shire International Licensing BV.

Intercept Announces Efficacy and Safety Data from Phase 3 REGENERATE Study in Liver Fibrosis due to NASH to be Presented at NASH-TAG Conference 2023

Retrieved on: 
Wednesday, January 4, 2023

MORRISTOWN, N.J., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced two abstracts on obeticholic acid (OCA) will be presented at the NASH-TAG Conference 2023.

Key Points: 
  • MORRISTOWN, N.J., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced two abstracts on obeticholic acid (OCA) will be presented at the NASH-TAG Conference 2023.
  • The conference will be held from January 5 – 7, 2023, in Park City, Utah.
  • “We are looking forward to joining clinicians, researchers and industry peers in-person this year at NASH-TAG 2023 to share additional data from the second interim analysis of our pivotal Phase 3 REGENERATE study,” said M. Michelle Berrey, M.D., MPH, President of R&D and Chief Medical Officer of Intercept.
  • “These data demonstrate the robust antifibrotic effect of OCA, as well as its favorable long-term safety profile, and ultimately reaffirm our belief that OCA can be an important treatment for people living with fibrosis due to NASH.”
    Presentations at the NASH-TAG Conference 2023 include:
    “Focused Monitoring and Management Guidance Reduces the Incidence of Hepatic Safety Events: Results from the Phase 3 REGENERATE Trial of Obeticholic Acid for Nonalcoholic Steatohepatitis” Abstract # 33
    The use of OCA for fibrosis due to NASH is investigational and has not been approved by the U.S. Food and Drug Administration, the European Commission or any other health authority.

Agenus to Present Botensilimab Data at Late-Breaking Oral Session at ASCO-GI

Retrieved on: 
Wednesday, December 21, 2022

LEXINGTON, Mass., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Agenus Inc .

Key Points: 
  • LEXINGTON, Mass., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Agenus Inc .
  • (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced the Company will present expanded data on botensilimab in combination with balstilimab at the American Society of Clinical Oncology – Gastrointestinal Cancers Symposium (ASCO-GI), to be held January 19-21, 2023, in San Francisco, CA.
  • Expanded data from the microsatellite stable colorectal (MSS-CRC) expansion cohort of the Phase 1 study of botensilimab (a multifunctional Fc-enhanced anti-CTLA-4) in combination with balstilimab (anti-PD-1) in cold (immunotherapy-resistant) tumors, will be presented at a late-breaking oral session on January 21, 2023, at 10:00am ET.
  • Data presented at the conference will be available to view in the Publications section of the Agenus website (https://agenusbio.com/publications) following the ASCO-GI Meeting.

Renesas Announces Its First Wi-Fi Development Kit with Support for New Matter Protocol

Retrieved on: 
Thursday, January 5, 2023

Renesas Electronics Corporation (TSE: 6723), a premier supplier of advanced semiconductor solutions, today announced its first development kit that includes support for the new Matter protocol.

Key Points: 
  • Renesas Electronics Corporation (TSE: 6723), a premier supplier of advanced semiconductor solutions, today announced its first development kit that includes support for the new Matter protocol.
  • View the full release here: https://www.businesswire.com/news/home/20230105005397/en/
    The Matter protocol promises to solve the problem of interoperability for smart home devices.
  • The first Renesas product to support the Matter protocol is the DA16200 Ultra-Low Power Wi-Fi Modules Development Kit .
  • Renesas is sampling the DA16200 Development Kit with Matter support to lead customers now and expects to release it broadly by the end of this quarter.